PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer (HALO-109-202)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2015 by Halozyme Therapeutics
Information provided by (Responsible Party):
Halozyme Therapeutics Identifier:
First received: April 22, 2013
Last updated: February 5, 2016
Last verified: October 2015

To compare the treatment effect of PEGPH20 combined with nab-paclitaxel and gemcitabine (PAG) to nab-paclitaxel and gemcitabine (AG) in subjects with Stage IV pancreatic cancer.

The Phase 2 will study safety and treatment effect in 237 subjects (2:1 randomization, PAG:AG), preceded by two run-in phases (the first to assess safety and tolerability and a second to assess a new formulation of PEGHP20), 16 subjects total (randomized 3:1).

Condition Intervention Phase
Metastatic Pancreatic Cancer
Drug: PEGPH20+nab-paclitaxel+gemcitabine
Drug: nab-paclitaxel + gemcitabine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Resource links provided by NLM:

Further study details as provided by Halozyme Therapeutics:

Primary Outcome Measures:
  • Estimate the PFS duration of PEGPH20 combined with NAB plus GEM [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • To evaluate the thromboembolic events in subjects treated in the PAG arm [ Time Frame: Ongoing ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Estimate relative benefit of PAG treatment vs. AG treatment, as assessed by the PFS ratio [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Estimate relative benefit of PAG vs AG treatment as assessed by the PFS hazard ratio based on subject tumor-associated HA levels [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Estimate ORR as defined by RECIST 1.1 of PAG treatment and the relative benefit of PAG treatment vs AG treatment [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • To estimate the OS duration of PAG treatment and the relative benefit of PAG treatment vs AG treatment, as assessed by the OS hazard ratio. [ Time Frame: 16 months ] [ Designated as safety issue: Yes ]
  • To evaluate the safety and tolerability profile of PAG and AG treatment groups [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • To characterize the plasma PK of PEGPH20 when given in combination with NAB + GEM [ Time Frame: Various visits and timepoints ] [ Designated as safety issue: No ]

Estimated Enrollment: 237
Study Start Date: April 2013
Estimated Study Completion Date: July 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PEGPH20
Drug: PEGPH20+nab-paclitaxel+gemcitabine
PEGPH20 3ug/kg + nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2. PEGPH20 given IV x2/week for Cycle 1 and weekly for Cycle 2 and beyond. Nab-paclitaxel and gemcitabine given IV x1/week for 3 weeks for all cycles.
Other Names:
  • Abraxane
  • Gemzar
Active Comparator: nab-paclitaxel + gemcitabine
nab-paclitaxel + gemcitabine x1/week
Drug: nab-paclitaxel + gemcitabine
nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 given IV x1/week 3/4 weeks per cycle
Other Names:
  • Abraxane
  • Gemzar

Detailed Description:
  1. Phase 2, multicenter open-label randomized study with two run-in phases. The first run-in phase was to evaluate safety and tolerability of PEGPH20 + Nab-paclitaxel + Gemcitabine vs. Nab-paclitaxel + Gemcitabine. A second run-in phase was to evaluate a new formulation of PEGPH20.

    Phase 2 will be an open-label randomized study with same study drugs evaluating safety and efficacy.

  2. Subjects must have newly diagnosed stage 4 untreated metastatic pancreatic ductal cancer diagnosed by a standard of Care CT scan within 20 days of dosing and meet all inclusion/exclusion criteria.
  3. Treatment consists of 4 week treatment cycles with Week 4 of every cycle, a wash-out week. In Cycle 1, PEGPH20 will be administered twice per week with Nab-paclitaxel + Gemcitabine given once/week 2-4 hrs after PEGPH20 and nab-paclitaxel + gemcitabine alone
  4. Safety parameters include medical history, physical exams, adverse event and Concomitant med collection, Doppler and CT scans for thromboembolic events, prophylactic enoxaparin, Karnofsky Performance scale, Immunogenicity, Hematology, Chemistry, coagulation, Weight/body surface area (BSA) for dosing, ECG and pharmacokinetics (PK) and Hyaluronan (HA) catabolite levels. Efficacy parameters include standard of care CT scans, CA19-9, tumor analysis of HA.
  5. Subjects continue in study until disease progression, adverse event/toxicity, death or either the subject/sponsor discontinues the study.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Signed Informed consent
  • Histologically confirmed Stage IV pancreatic ductal adenocarcinoma w/ documented disseminated neoplasm to liver and /or lung. Must have archival or fresh tissue (block /slides) available pre-dose.
  • One or more measurable metastatic tumors measurable on CT san per Response Evaluation Criteria in Solid Tumors (RECIST v.1.1 ), excluding the primary lesion.
  • No previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease.
  • Karnofsky Performance Status >= 70%
  • Life expectancy >= 3 mos
  • Age >= 18 years
  • Screen labs of Hemoglobin, platelets, absolute neutrophil count (ANC), bilirubin, AST, ALT, serum creatinine, serum albumin, PT/INR, and PTT within specified values/criteria per protocol prior to dosing.

Key Exclusion Criteria:

  • Non metastatic pancreatic ductal adenocarcinoma
  • Evidence of deep vein thrombosis (DVT) or pulmonary embolism (PE) or other known thromboembolic event present during screening period.
  • Known Central nervous system involvement, brain metastasis
  • New York(NY) Heart Association Class III or IV cardiac disease or Myocardial infarction within the past 12 months.
  • Prior history of cerebrovascular accident or transient ischemic attack
  • Pre-existing carotid artery disease
  • Active, uncontrolled bacterial, viral or fungal infection requiring systemic therapy.
  • Current use of megestrol acetate (Use within 10 days of Day 1)
  • Known infection with human immunodeficiency virus, Hepatitis B, or Hepatitis C
  • History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early state prostate cancer, or curatively-treated cervical cancer in-situ.
  • Contraindication to heparin as per NCCN guidelines
  • Previous major bleed (bleeding requiring transfusion of red blood cells) on LMWH
  • Any other disease, metabolic dysfunction, physical examination finding or clinical lab finding that leads to reasonable suspicion of disease or condition that contraindicates the use of an investigational drug, that may affect interpretation of results, or render the subject at a high risk of treatment complications.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01839487

Contact: Dimitrios Chondros, MD 858-794-8889
Contact: Angie Schinkel 858-794-8889

  Hide Study Locations
United States, Alabama
Alabama Oncology Active, not recruiting
Birmingham, Alabama, United States, 35213
University of South Alabama Mitchell Cancer Institute Active, not recruiting
Mobile, Alabama, United States, 36604
United States, Arizona
Banner MD Anderson Cancer Center Active, not recruiting
Gilbert, Arizona, United States, 85234
Mayo Clinic - Scottsdale Active, not recruiting
Scottsdale, Arizona, United States, 85259
Arizona Oncology Associates, PC Active, not recruiting
Tucson, Arizona, United States, 85704
United States, Arkansas
Highlands Oncology Group Active, not recruiting
Fayetteville, Arkansas, United States, 72703
United States, California
Providence St Joseph Medical Center Active, not recruiting
Burbank, California, United States, 91505
Scripps Cancer Center Active, not recruiting
La Jolla, California, United States, 92037
UCSD - Moore's Cancer Center Active, not recruiting
La Jolla, California, United States, 92093
Cedars-Sinai Medical Center Active, not recruiting
Los Angeles, California, United States, 90048
University of California Medical Center Active, not recruiting
Orange, California, United States, 92868
Pacific Hematology Oncology Associates Active, not recruiting
San Francisco, California, United States, 94115
Saint Helena Hospital Active, not recruiting
St. Helena, California, United States, 94574
The Oncology Institute of Hope and Innovation Recruiting
Whittier, California, United States, 90603
Principal Investigator: Merrill Shum, MD         
United States, Colorado
University of Colorado Cancer Center Active, not recruiting
Aurora, Colorado, United States, 80045
Rocky Mountain Cancer Center Active, not recruiting
Denver, Colorado, United States, 80218
United States, Connecticut
Stamford Hospital Active, not recruiting
Stamford, Connecticut, United States, 06902
United States, District of Columbia
Georgetown University Medical Center Active, not recruiting
Washington, District of Columbia, United States, 20007
United States, Florida
University of Miami, Sylvester comprehensive Cancer Center Active, not recruiting
Miami, Florida, United States, 33136
H. Lee Moffit Cancer Center Active, not recruiting
Tampa, Florida, United States, 33612
United States, Georgia
Piedmont Hospital Active, not recruiting
Atlanta, Georgia, United States, 30318
United States, Illinois
Loyola University Medical Center Active, not recruiting
Maywood, Illinois, United States, 60153
United States, Kentucky
Norton Cancer Institute - Norton HealthCare Pavilion Active, not recruiting
Louisville, Kentucky, United States, 40202
United States, Maryland
Johns Hopkins University Hospital Active, not recruiting
Baltimore, Maryland, United States, 21231
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Principal Investigator: Andrea Bullock, MD         
Lahey Clinic Active, not recruiting
Burlington, Massachusetts, United States, 01805
University of Mass Medical School Active, not recruiting
Worcester, Massachusetts, United States, 01655
United States, Michigan
University of Michigan Active, not recruiting
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
Virginia Piper Cancer Institute Active, not recruiting
Minneapolis, Minnesota, United States, 55407
Unniversity of Minnesota Active, not recruiting
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Research Medical Center Active, not recruiting
Kansas City, Missouri, United States, 64132
Washington University School of Medicine Active, not recruiting
St Louis, Missouri, United States, 63110
United States, Nevada
Comprehensive Cancer Centers of Nevada Active, not recruiting
Las Vegas, Nevada, United States, 89169
United States, New Jersey
St. Joseph's Regional Medical Center Active, not recruiting
Paterson, New Jersey, United States, 07503
United States, New York
Roswell Park Cancer Institute Active, not recruiting
Buffalo, New York, United States, 14263
North Shore Long Island Jewish Health System Active, not recruiting
Lake Success, New York, United States, 11042
Columbia University Medical Center Active, not recruiting
New York, New York, United States, 10032
Mount Sinai Medical Center Active, not recruiting
New York, New York, United States, 10029
University of Rochester Active, not recruiting
Rochester, New York, United States, 14642
United States, North Carolina
Carolinas HealthCare System Active, not recruiting
Charlotte, North Carolina, United States, 28204
United States, Ohio
Gabrail Cancer Center Active, not recruiting
Canton, Ohio, United States, 44718
United States, Oklahoma
University of Oklahoma Health Science Center Active, not recruiting
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
UPMC Cancer Center Active, not recruiting
Pittsburgh, Pennsylvania, United States, 15213
United States, South Carolina
Greenville Health System Active, not recruiting
Greenville, South Carolina, United States, 29605
United States, Texas
Texas Oncology - Baylor Active, not recruiting
Dallas, Texas, United States, 75246
Cancer Care Centers of South Texas Active, not recruiting
New Braunfels, Texas, United States, 78130
Texas Oncology Active, not recruiting
Tyler, Texas, United States, 75702
United States, Washington
Columbia Basin Hematology and Oncology Active, not recruiting
Kennewick, Washington, United States, 99336
Seattle Cancer Care Alliance Active, not recruiting
Seattle, Washington, United States, 98109
NorthWest Medical Specialties, PLLC Active, not recruiting
Tacoma, Washington, United States, 98405
United States, Wisconsin
University of Wisconsin Hospitals and Clinics Active, not recruiting
Madison, Wisconsin, United States, 53792
Froedtert Hospital, Medical College of Wisconsin Active, not recruiting
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Halozyme Therapeutics
Study Director: Dimitrios Chondros, MD Halozyme Therapeutics
  More Information

No publications provided

Responsible Party: Halozyme Therapeutics Identifier: NCT01839487     History of Changes
Other Study ID Numbers: HALO-109-202 
Study First Received: April 22, 2013
Last Updated: February 5, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Halozyme Therapeutics:
pancreatic ductal carcinoma(PDA)
Pancreatic ductal carcinoma

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Site
Pancreatic Diseases
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators processed this record on February 09, 2016